Introduction {#Sec1}
============

Diffuse large B-cell lymphoma (DLBCL) is the most common subtype of non-Hodgkin's lymphoma, and it comprises approximately 30--40% of new lymphoma diagnoses in the USA \[[@CR1], [@CR2]\]. Recently, using expression microarray technology, several studies have shown that DLBCL can be divided into three subgroups based on gene expression profiles. These include germinal center B-cell-like (GCB), activated B-cell-like (ABC), and type 3 \[[@CR3], [@CR4]\]. Independent of other established prognostic markers such as the International Prognostic Index (IPI) \[[@CR5]\], patients with a gene expression profile resembling a GCB type have significantly better overall survival than those with an ABC type; the type 3 group also has a poor prognosis, but it represents a heterogeneous category that is not yet well defined. Immunohistochemistry (IHC), a technology that is more widely available and economically feasible than expression microarrays, has been attempted for classifying DLBCL into GCB and non-GCB subgroups using different combinations of CD10, BCL-6, MUM1, and/or CD138 \[[@CR6]--[@CR9]\]. The majority of these studies have confirmed significantly better survival for GCB group suggesting that IHC is an important tool to validate the microarray findings in pathology practice \[[@CR6]--[@CR9]\].

The nuclear factor-κB (NF-κB) signaling pathway plays an important role in regulating the survival of normal and malignant B-cells by controlling the expression of multiple cell death regulatory pathways \[[@CR10], [@CR11]\]. The recent development of NF-κB inhibitors may make this pathway a potential therapeutic target for lymphoma \[[@CR12]\]. NF-κB target genes can enhance cell survival by modulating TNFα signaling, inhibiting FAS-mediated apoptosis, and limiting the activity of BCL2 family members \[[@CR11]\]. The role of NF-κB pathways in different subgroups of DLBCL has not been well elucidated \[[@CR12]\]. Although some studies suggest that constitutive activation of NF-κB contributes to the sustained oncogenicity of the ABC-like DLBCL \[[@CR12]--[@CR14]\], a recent expert review encouraged cautious interpretation of this data \[[@CR12]\]. Studies have also suggested that *c-REL* amplification, a subunit of the REL/NF-κB family, is more commonly observed in GCB-type DLBCL than ABC-type DLBCL \[[@CR4]\]; however, *c-REL* amplification is not frequently associated with NF-κB activation (nuclear c-REL expression) \[[@CR10], [@CR11], [@CR15]\].

Activation of the NF-κB pathway in a B-cell lymphoma can be preliminarily assessed by determining the nuclear localization of NF-κB subunits such as c-REL \[[@CR16]--[@CR18]\]. In the inactive status, NF-κB heterodimers (c-REL or REL homolog A and NF-κB1) reside in the cytoplasm bound to an inhibitor of kappa B signaling (I-κB) \[[@CR11]\]. During NF-κB activation, I-kappa kinase (I-κK) phosphorylates I-κB resulting in the dissociation of the inhibitor from the cytoplasmic NF-κB heterodimer. Thereafter, the freed (activated) NF-κB heterodimer, including c-REL, translocates to the nucleus where it induces the transcription of NF-κB target genes \[[@CR11]\].

Using c-REL nuclear expression by IHC as a surrogate marker for NF-κB activation, studies have demonstrated that primary mediastinal large B-cell lymphoma cases show homogeneously strong c-REL nuclear staining, whereas the c-REL staining pattern in other DLBCL is more variable \[[@CR16], [@CR17], [@CR27]\]. However, these studies have not attempted to correlate c-REL expression with clinical parameters. The main goal of the current study was to evaluate the impact of c-REL expression and GCB status on the clinical outcome in DLBCL patients using IHC.

Materials and methods {#Sec2}
=====================

Case selection {#Sec3}
--------------

DLBCL cases from 1992--2001 were retrospectively retrieved from the archives of the Department of Pathology at the Medical College of Wisconsin and The Methodist Hospital. Sixty-eight cases (44 cases from a tissue microarray with each case consisting of three 1.2-mm cores and 24 cases from whole tissue sections) of newly diagnosed de novo DLBCLs with adequate clinical follow-up information were included in the study. This cohort included 15 cases from a previous study \[[@CR6]\]. Cases with a preceding diagnosis of low-grade lymphoma or a history of having received immunosuppressive therapy were excluded from the study. This cohort of patients did not include DLBCL cases occurring in the central nervous system (CNS) or mediastinum, because primary DLBCL of the CNS and primary mediastinal large B-cell lymphoma are considered distinct clinicopathologic subgroups of DLBCL by WHO classification \[[@CR20]\]. A single case of DLBCL occurring in bone in our file were excluded in this study since we could not determine if this case represented primary lymphoma or secondary involvement of lymphoma based on the clinical information available. The pertinent clinical information for each case was obtained by reviewing the tumor registry records and/or patient medical charts. This study was approved by the Institutional Review Boards of the participating institutions.

Histopathology {#Sec4}
--------------

All cases were reviewed to confirm that morphologic characteristics fulfilled the criteria of DLBCL by the WHO classification \[[@CR20]\]. The H&E-stained sections of all cases show a neoplasm of large B lymphoid cells with nuclear size equal to or exceeding normal macrophage nuclei or more than twice the size of a normal lymphocyte that has a diffuse growth pattern.

Immunohistochemistry {#Sec5}
--------------------

Immunohistochemical staining was performed using antibodies against c-REL and a panel of GC B-cell (CD10 and BCL-6) and activation (MUM1/IRF4) markers as previously published \[[@CR6]\]. For c-REL staining, the slides were pretreated with Citrate (DAKO USA, Carpinteria, CA, USA) for 30 min in a steamer. Primary rabbit anti-c-REL(AB-1) antibody (1:25dilution; Calbiochem/EMD Bioscience, Inc, San Diego, CA, USA) was applied in DAKO diluent for 1 h. The slides were washed, and the Dual Envision Kit (DAKO) was then applied for 30 min. After further washing, immunoperoxidase staining was developed using a diaminobenzidine chromogen kit (DAKO). CD10, BCL-6, and MUM1/IRF4 staining were performed as previously described \[[@CR6]\].

Two hematopathologists (CVC and CCC) independently reviewed each case and assigned a semiquantitative score for the expression of each antigenic marker without the knowledge of clinical information. Each case was evaluated by visual estimation and recorded in 10% increments. Any discrepancies were resolved by reviewing slides with a multi-headed microscope to achieve consensus. Expression of each marker was considered positive when \>20% of large neoplastic lymphocytes stained positively at the appropriate subcellular locations (c-REL, BCL-6, and MUM1/IRF4 with nuclear and/or cytoplasmic staining; CD10 with membranous and/or cytoplamic staining). This cutoff has been commonly used in previous studies evaluating protein expression by IHC \[[@CR21]--[@CR23]\].

Statistical methods {#Sec6}
-------------------

Demographics were summarized using frequencies and percentages for categorical variables and median and range for continuous variables. Survival probabilities were calculated using the Kaplan--Meier analysis. All analyses were done using SAS v 5.0.1.

Results {#Sec7}
=======

The cohort contained 36 females (53%) and 32 males (47%), ranging in age from 16 to 88 years (mean 63 years). The median follow-up was 43 months (range 0--142 months) and the median follow-up among survivors was 66 months (range 14--142 months). All patients received Cytoxan, Doxorubicin, Vincristine, and Prednisone- (CHOP-) based chemotherapy without Rituximab. We were able to abstract IPI scores in 34 cases. Twenty-three had low IPI scores (≤2, low risk and low-intermediate risk groups) and 11 had high IPI scores (\>3, high-intermediate risk and high risk groups).

Forty-four cases (65%) were positive for c-REL nuclear expression. They showed moderate to strong nuclear and cytoplasmic staining of 20% to 100% of the large neoplastic lymphocytes (Fig. [1](#Fig1){ref-type="fig"}). The remaining 24 cases (35%) were negative for c-REL expression. The majority of the c-REL negative cases showed weak to moderate cytoplasmic staining in large neoplastic lymphocytes with rare scattered nuclei showing weak staining (Fig. [1](#Fig1){ref-type="fig"}). The frequencies of expression for CD10, BCL-6, and MUM1 in the cases studied were as follows: 29 of 68 (43%), 50 of 68 (74%), and 44 of 68 (65%; Table [1](#Tab1){ref-type="table"}). The frequencies of antigen expression were quite comparable between the cases using tissue microarray and the cases using whole tissue section, suggesting that there was no sampling bias using tissue microarray. Based on these results, 24 cases (35%) were GCB phenotype (CD10+ and/or BCL-6+, MUM1-), and 44 cases (65%) were non-GCB phenotype (MUM1+, regardless of CD10 and BCL-6 expression) using the classification scheme by Chang et al. \[[@CR6]\]. Using Hans's classification methods \[[@CR7]\], 34 cases (50%) were GCB phenotype (CD10+ or CD10-/BCL6+/MUM1-) and 34 cases (50%) were non-GCB phenotype (CD10-/BCL6- or CD10-/BCL6+/MUM1+). Fig. 1Representative photomicroghs of c-REL expression in DLBCL (original magnification, ×400; immunohistochemical c-REL stain). **a**, **b** Negative c-REL expression cases: Negative nuclear expression with weak (**a**) and moderate (**b**) cytoplasmic expression, respectively. **c** Case scored as positive c-REL showing both nuclear and cytoplasmic staining; note small lymphocytes without nuclear or cytoplasmic stainingTable 1Correlation of nuclear c-REL expression with other immunohistochemical markers in DLBCLImmunohistochemical markersParameter (*n*)Nuclear c-REL expression*P* valuePositive (*n* = 44)Negative (*n* = 24)CD10Positive292090.5262^a^Negative392415BCL6Positive5030200.1759^a^Negative18144MUM1/IRF4Positive4429150.7786^a^Negative24159GCB vs non-GCB phenotypeNon-GCB4429150.7786^a^GCB24159^a^Chi Square

Of note, there was no statistically significant difference in the frequency of c-REL expression between the GCB and non-GCB phenotype and other immunohistochemical markers (CD10, BCL-6, or MUM1; Table [1](#Tab1){ref-type="table"}). We further evaluated multiple clinical parameters in relation to the presence or absence of nuclear c-REL staining. No statistically significant correlation was observed between c-REL nuclear expression and age, sex, extranodal sites, or IPI (Table [2](#Tab2){ref-type="table"}). Table 2Comparison of clinical features in patients with or without positive nuclear c-REL Expression in DLBCLClinical parametersParameter (*n*)Nuclear c-REL expression*P* valuePositive (*n* = 44)Negative (*n* = 24)Age\<60231580.9497^a^≥60452916SexMale3219130.3858^a^Female362511SiteNodal3721160.1340^a^Extranodal31238IPILow (0--2)231670.8499^a^High (3--5)1183^a^Chi Square

The GCB subgroup showed better overall survival (OS) than the non-GCB subgroup (50% cumulative survival not reach for GCB compared to 25--26 months for non-GCB, Kaplan--Meier survival analysis, *p* = 0.016, Breslow--Gehan--Wilcoxon test, Fig. [2](#Fig2){ref-type="fig"}a), using Chang's classification scheme. The results were similar using Han's scheme for defining GC and non-GC status (data not shown). Using only c-REL expression, no correlation with OS was observed (Fig. [2](#Fig2){ref-type="fig"}b). The finding of no correlation with OS remained the same when the data was analyzed using the 50% cutoff as defined by Rodig et al. \[[@CR16]\] for c-REL expression (Fig. [2](#Fig2){ref-type="fig"}c). However, when combining c-REL nuclear expression with GCB vs. non-GCB phenotype as defined by Chang et al., cases with a GCB phenotype and negative nuclear c-REL had a better OS (only one out of nine patients died at 96 months with a median follow-up of 72 months) than cases with a GCB phenotype and positive nuclear c-REL (six out of 16 patients died at a median of 18 months, range 1 to 46 months, *p* = 0.045, Breslow--Gehan--Wilcoxon test (Fig. [2](#Fig2){ref-type="fig"}d)). When the GCB or non-GCB were defined using Han's classification, the similar trend of having a better OS toward the group of patients with GCB phenotype and negative nuclear c-REL was observed, but the difference was not statistically significant (data not shown). Of noted, there was no statistically difference of IPI among c-REL positive or c-REL negative in the GCB phenotype subgroups (data not shown). Among the patients with non-GCB phenotype, c-REL expression did not impact the OS (data not shown). Fig. 2Overall survival (OS) curves by Kaplan--Meier survival analysis. **a** OS curves using GCB versus non-GCB phenotypes. **b** Negative c-REL versus positive c-REL expression by our criteria. **c** Negative c-REL versus positive c-REL expression by Rodig's criteria. **d** Only cases classified as GCB phenotype: negative c-REL versus positive c-REL expression

Discussion {#Sec8}
==========

Using c-REL nuclear expression by immunohistochemistry as a surrogate marker for NF-κB activation, our results suggest that DLBCL with a GCB phenotype and negative c-REL expression may have a better clinical outcome. Furthermore, c-REL expression does not correlate with either GCB or non-GCB phenotype or IPI score. Taken together, c-REL expression in combination with GCB or non-GCB phenotype evaluation may improve patient risk stratification in DLBCL. The detailed mechanisms leading to a better prognosis in the GCB subtype cases without c-REL expression remain to be elucidated. One possible mechanism would be increased susceptibility to chemotherapy imparted by a lack of NF-κB activation and its resultant reduction in anti-apoptotic signals in the neoplastic lymphocytes. Additionally, the observed decreased OS among cases of GCB phenotypes with c-REL nuclear expression suggests that the lymphoma cells, even with a good prognostic GCB phenotype, may become resistant to chemotherapeutic agents once the NF-κB pathway is activated. Therefore, these cases may benefit from the addition of an NF-κB inhibitor to the CHOP regimen. However, in cases with the non-GCB phenotype, the c-REL nuclear expression (NF-κB activation) does not correlate with OS suggesting that other pathways leading to the more aggressive clinical course may also be involved. It should be noted that our findings are somewhat limited by the nature of the retrospective study design since the treatment and clinical evaluation may be relatively heterogeneous.

Our c-REL immunohistochemical staining results largely correlate with those of previous studies. Others have also reported that c-REL expression in DLBCL is heterogeneous \[[@CR16], [@CR17], [@CR27]\]. Furthermore, in agreement with previous studies, we do not observe any correlation between clinical parameters and c-REL nuclear expression \[[@CR15]\]. However, the frequency of c-REL nuclear expression appeared higher in our study (65% vs. 18% to 44%, respectively) \[[@CR16]\]. This observation may be attributed to the use of different c-REL antibody dilution, different staining methodologies, different scoring criteria, and/or case selection bias. For example, Rodig et al. used more stringent nuclear scoring criteria with a cutoff of 50% of cells staining positive to be considered positive \[[@CR16]\]. These scoring criteria may have underestimated the number of cases with activated NF-κB signaling. When we used the same strict criteria to analyze our data, the results of the statistical analysis remained unchanged (Fig. [2](#Fig2){ref-type="fig"}c). Furthermore, we cannot compare our OS data with these studies since the correlation between c-REL nuclear expression and OS has not been attempted in these studies.

Our results suggest that there is no correlation between c-REL nuclear expression and GCB or non-GCB phenotypes by immunohistochemical staining. This is in contrast to previous experiments which reported that c-REL nuclear expression by immunofluorescence staining is more commonly observed in the ABC phenotype determined by expression microarray analysis \[[@CR15]\]. However, the difference described by Houldsworth et al. was not statistically significant (c-REL nuclear expression, 6/18 in GCB vs. 7/11 in non-GCB, *p* = 0.143, Fisher's Exact). These differences may be caused by the different c-REL detection methodologies (immunofluorescence vs. IHC) or the different GCB/non-GCB phenotype classification methodologies (expression microarray vs. IHC). Further studies using IHC to study the expression of NF-κB targeted gene activation are ongoing in our laboratory. These experiments may provide valuable insight into the role of NF-κB activation in the molecular pathogenesis of the different subtypes of DLBCL.

In the current study, all the data were analyzed using two published algorithms (one by our group and the other by Han et al.) for classifying GCB vs. non-GCB phenotype of DLBCL using IHC \[[@CR6], [@CR7]\]. Not surprisingly, two algorithms in general agree with each other relatively well since the only difference is that we consider any cases with MUM1 and CD10 expression as non-GCB while Han et al. consider CD10 expression regardless of MUM1 status as GCB. Nevertheless, the statistical significance of c-REL expression in GCB was observed using our classification algorithm but not by Han et al. although the latter algorithm also showed the similar trend. It would be of interest for the future similar studies to continue to use both algorithms to analyze the data to maximize the potential discoveries.

The patients in the current study were treated with CHOP without Rituximab rather than the current standard therapy of CHOP with Rituximab; the implication of our results in the latter setting will require further validation. Rituximab has an impact on the use of other prognostic markers such as BCL-2 or BCL-6 \[[@CR24], [@CR25]\]. Nevertheless, the prognostic significance of GCB vs. ABC subtype of DLBCL remains valid in a recent study by LLMPP consortium using microarray data \[[@CR26]\], although the prognostic significance of GCB vs. non-GCB using IHC remains not well defined \[[@CR27]\]. Our work should prompt the interest of the investigators to study c-REL expression in their patient cohort to evaluate the significance of our findings in the Rituximab era.

In summary, our data suggest that the evaluation of c-REL nuclear expression combined with GCB and non-GCB phenotyping by IHC may improve patient risk stratification in DLBCL. Further studies are needed to substantiate the clinical significance of our findings.
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